MX2022013207A - Metodos y composiciones para el tratamiento de cancer. - Google Patents

Metodos y composiciones para el tratamiento de cancer.

Info

Publication number
MX2022013207A
MX2022013207A MX2022013207A MX2022013207A MX2022013207A MX 2022013207 A MX2022013207 A MX 2022013207A MX 2022013207 A MX2022013207 A MX 2022013207A MX 2022013207 A MX2022013207 A MX 2022013207A MX 2022013207 A MX2022013207 A MX 2022013207A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating cancer
chimeric binding
same
Prior art date
Application number
MX2022013207A
Other languages
English (en)
Inventor
Christoph Rader
David Cheresh
Hiromi Wettersten
Sara Weis
Stephen Mccormack
Original Assignee
Alpha Beta Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Beta Holdings Llc filed Critical Alpha Beta Holdings Llc
Publication of MX2022013207A publication Critical patent/MX2022013207A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a agentes aglutinantes quiméricos y composiciones que los comprenden. La invención se refiere además a los polinucleótidos que codifican el agente de unión quimérico y los vectores y las células huésped que los comprenden. La invención se refiere además a métodos de uso de agentes de unión quiméricos para mediar en la citotoxicidad celular dependiente de anticuerpos de células cancerosas epiteliales y métodos de tratamiento de cánceres de células epiteliales.
MX2022013207A 2020-04-23 2021-04-23 Metodos y composiciones para el tratamiento de cancer. MX2022013207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063014550P 2020-04-23 2020-04-23
PCT/US2021/028775 WO2021216956A1 (en) 2020-04-23 2021-04-23 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
MX2022013207A true MX2022013207A (es) 2023-01-24

Family

ID=78270118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013207A MX2022013207A (es) 2020-04-23 2021-04-23 Metodos y composiciones para el tratamiento de cancer.

Country Status (11)

Country Link
US (1) US20230140868A1 (es)
EP (1) EP4110822A4 (es)
JP (1) JP2023523016A (es)
KR (1) KR20230019424A (es)
CN (1) CN115485301A (es)
AU (1) AU2021261003A1 (es)
BR (1) BR112022019939A2 (es)
CA (1) CA3172092A1 (es)
IL (1) IL296576A (es)
MX (1) MX2022013207A (es)
WO (1) WO2021216956A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102423686B1 (ko) * 2019-01-10 2022-07-21 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
WO2023056326A1 (en) * 2021-09-30 2023-04-06 Alpha Beta Holdings, Llc Compositions and methods for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69828154T2 (de) * 1997-03-12 2005-06-23 Smithkline Beecham Corp. Anti-alphavbeta3 humanizierte monoklonale antikörper
CA2577329A1 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
JP2020512978A (ja) * 2017-03-31 2020-04-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法

Also Published As

Publication number Publication date
JP2023523016A (ja) 2023-06-01
AU2021261003A1 (en) 2022-10-20
EP4110822A4 (en) 2024-04-10
EP4110822A1 (en) 2023-01-04
KR20230019424A (ko) 2023-02-08
CN115485301A (zh) 2022-12-16
IL296576A (en) 2022-11-01
WO2021216956A1 (en) 2021-10-28
BR112022019939A2 (pt) 2022-12-13
US20230140868A1 (en) 2023-05-11
CA3172092A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2022013207A (es) Metodos y composiciones para el tratamiento de cancer.
JOP20200307A1 (ar) جزيئات ربط ضد bcma واستخداماتها
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
CR20200465A (es) Agentes anticuerpos anti-cd25
DK1896507T3 (da) Anti-CD71-monoklonale antistoffer og anvendelser deraf til behandling af maligne tumorceller
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
MX2020009463A (es) Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor.
UA102891C2 (uk) Повні людські антитіла, специфічні до cadm1
MX2022007288A (es) Agentes de union a ilt3 y metodos de uso de los mismos.
WO2019023315A3 (en) RAC INHIBITORS
PH12020500664A1 (en) C3-binding agents and methods of use thereof
MX2023002017A (es) Composiciones y métodos para tratar cánceres positivos para ceacam.
MX2022005330A (es) Moleculas de union multiespecificas con scfv en el extremo nterminal.
MX2022007833A (es) Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
MX2020003089A (es) Analogos de tailanstatina.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2023002041A (es) Composiciones y métodos para tratar cánceres positivos para mesotelina.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
MX2022013259A (es) Composiciones y metodos de tratamiento del cancer con receptores de antigeno quimerico.
WO2018193476A3 (en) ANTICANCER COMPOUNDS
PH12020551454A1 (en) Anti-cd25 for tumour specific cell depletion
MX2023005171A (es) Composiciones y metodos para tratamiento de cancer solido.
MX2021013117A (es) Composiciones y metodos para el tratamiento del cancer.
MX2022015475A (es) Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma.
MX2021009195A (es) Metodos y composiciones para el tratamiento del cancer.